How to Sell a Home Health Agency in 2026

Home health M&A has been in a strange place since the Patient-Driven Groupings Model (PDGM) reset reimbursement in 2020 and CMS started cutting the base rate every year since. Multiples have come down, but the strategic appetite from the big platforms — Enhabit, BrightSpring, Aveanna, Addus HomeCare, Amedisys (now part of UnitedHealth's Optum), LHC Group (also Optum), BAYADA, Compassus, and PE-backed operators like Help at Home — hasn't gone away. If you run a clean, Medicare- certified agency with strong star ratings in a desirable market, you still have buyers.

The key word is "clean." The worst diligence experiences I've seen in healthcare have been in home health, because the business is regulatory-heavy, documentation- intensive, and exposed to RAC audits, UPIC audits, and the targeted probe and educate (TPE) process. If your agency has unresolved audit exposure or weak clinical documentation, it will show up in diligence. Fix it before you sell.

The CHOW Process Takes Longer Than You Think

A Medicare home health change of ownership (CHOW) is not a quick administrative filing. It's a regulated process that requires CMS notice, state survey agency coordination, and typically takes 6-12 months from submission to approval. During that time, the agency continues billing under the seller's Medicare provider number under an assignment agreement, and the seller remains legally responsible for compliance.

There are two ways to structure: a true CHOW (the seller's CCN transfers) or a stock/equity purchase where the legal entity stays the same and only ownership changes hands. Most strategic buyers prefer the equity purchase structure because it avoids resurveying and preserves the star rating. Smaller PE roll-ups sometimes prefer asset purchases with CHOW because they want to isolate historical liabilities — but that means a fresh survey and, potentially, a reset star rating.

Before you go to market, pull your CMS-855A on file, verify your correspondence address is current, and make sure your state home health license is clean and has at least 18 months of runway. If your license is up for renewal in the next 12 months, renew it before the sale — buyers hate doing CHOW work against an expiring license.

Star Ratings Drive Your Multiple

Home health valuations are increasingly driven by CMS Care Compare star ratings — both the Quality of Patient Care star rating and the Patient Survey (HHCAHPS) star rating. A 4.5-star agency trades at a meaningfully higher multiple than a 3-star agency because buyers know that Medicare Advantage plans, hospital discharge planners, and ACOs all use star ratings as referral filters.

Before going to market, pull your agency's Care Compare profile and understand every measure. The Quality of Patient Care composite is weighted across several process measures (timely initiation of care, drug education, flu vaccination) and outcome measures (improvement in ambulation, transferring, bathing, bed transferring, and acute care hospitalization rate). Outcome measures move your star rating more than process measures, and they take 6-12 months of consistent OASIS accuracy to improve.

The acute care hospitalization (ACH) rate is the single biggest driver. Agencies under 14% ACH are in the top quartile. Agencies over 17% drag down the composite and get discounted on sale. If your ACH rate is high, invest in a frontloading visit protocol and a telehealth remote patient monitoring program — both are proven to move the number.

HHCAHPS is the other half. Willingness to recommend and overall rating of care are the measures that move your survey star rating fastest. If you're below 4 stars on HHCAHPS, there are specific operational fixes — field clinician communication training, post-admission phone calls, service recovery protocols — that can move the number within two quarters.

PDGM Economics and Case Mix

Under PDGM, every 30-day period is reimbursed based on clinical grouping, functional impairment level, comorbidity adjustment, admission source, and timing. Buyers underwrite your agency on case mix weight (CMW) and the trend in your LUPA rate (Low Utilization Payment Adjustments). A good agency runs CMW around 1.05-1.15 with LUPA rates under 8%. Agencies with CMW under 1.0 and LUPA rates over 12% are leaving revenue on the table and will be discounted by buyers.

The fix is clinical documentation improvement (CDI) and OASIS accuracy. Agencies that have invested in coding and OASIS review programs — through vendors like SimiTree, Healthcare Provider Solutions, or Corridor — routinely move CMW 0.05-0.10 and add 4-8% to net revenue. That flows straight to EBITDA and directly to your sale price.

Referral source mix matters too. Hospital-referred episodes (admission source institutional) pay higher than community referrals under PDGM. A diversified referral base — health systems, skilled nursing facilities, physician groups, ACOs, MA plans — signals durability. Agencies with 50%+ of referrals from a single hospital get discounted for concentration risk.

What PE Buyers Actually Want

The PE buyer landscape has consolidated but it's still active. Platforms I see showing up regularly include Help at Home (The Vistria Group), BrightSpring (KKR/ Walgreens), Modivcare, Addus HomeCare, and a tail of regional PE-backed agencies like Trilogy Home Healthcare, Caretenders, and Three Oaks Hospice & Home Health.

Here's what moves the needle for PE buyers in home health M&A:

• Scale. Agencies with 400+ average daily census are platform candidates. Smaller agencies are add-ons at lower multiples.
• Geography. Certificate-of-Need states (New York, New Jersey, Georgia, South Carolina, Illinois) trade at premiums because new entry is limited.
• Medicare Advantage readiness. As traditional Medicare shifts to MA, buyers want agencies with value-based care contracts, episodic bundles, and the operational muscle to manage capitated lives.
• Clean compliance history. No unresolved ZPIC/UPIC audits, no outstanding ADRs, no corporate integrity agreements. Any open audit is a deal killer.
• Clinician retention. RN and therapist turnover under 25% annually. Staffing is the binding constraint in home health, and buyers know it.

Running the Process

For agencies doing $2M+ in EBITDA, hire a healthcare banker with home health specialization. Firms like Mertz Taggart, The Braff Group, Stoneridge Partners, Provident, and SunTrust Robinson Humphrey (Truist Securities) regularly run home health processes and know the PE and strategic buyer universe.

Budget for sell-side quality of earnings plus a clinical compliance review. The compliance review is unique to healthcare — a firm like SimiTree or Fazzi Associates will audit a chart sample, review your OASIS accuracy, and document your billing compliance. Buyers will do their own version, but having your own report in hand lets you drive the narrative.

The process typically runs 7-10 months. Deal structures commonly include a 10-20% escrow held for 18-24 months against representations and warranties, particularly Medicare billing compliance. Expect a 1-2 year earnout tied to EBITDA and star rating maintenance. Don't accept an earnout tied to referral volume — it's outside your control post-close.

What to Fix Before You Go to Market

OASIS accuracy and CDI. This is the single highest-ROI pre-transaction investment in home health. A focused 6-month CDI engagement can move case mix weight 0.05-0.10, add 4-8% to net revenue per episode, and flow directly to EBITDA.

Close out any open audits. ADRs, TPE rounds, UPIC inquiries — get them resolved, documented, and off the active list before engaging a banker. Buyers will ask, and any open audit exposure is a deal structure problem.

Invest in star rating improvement. Acute care hospitalization rate is the single biggest star rating lever. Implement frontloading visits, remote patient monitoring, and a 24/7 triage line. Moving from 3 stars to 4 stars can add 1-2 turns of EBITDA multiple at exit.

Diversify referral sources. If one hospital system is over 40% of your admissions, you have a concentration problem. Build referral relationships with SNFs, physician groups, MA plan care coordinators, and community discharge planners before you go to market.

The Bottom Line

Home health is a harder market than it was in 2019 — PDGM cuts, staffing challenges, and increased audit activity have all compressed multiples. But quality operators with 4+ star ratings, clean compliance, strong clinical outcomes, and scale in good geographies still get done at 6-9x EBITDA. The sellers who get there do the unglamorous work 12-18 months before a sale: OASIS accuracy, CDI, clinician retention, and compliance remediation. That's what separates a premium exit from a grind.